The ATP Study: Autologous platelet-leucocyte rich plasma treatment in achillestendinopathy to speed up healing and shorten the return to activity time.

The ATP Study: Autologous platelet-leucocyte rich plasma treatment in achillestendinopathy to speed up healing and shorten the return to activity time. - Achillestendinopathy and P-LRP treatment

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON33326

Enrollment

126

Registered

2009-08-17

Start date

2010-08-02

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

achilles tendonitis/tendinosis Achillestendinopathy

Interventions

Ultrasound guided injection of platelet-leucocyte rich plasma in Achillestendinopathy.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Clinical diagnosis of Achillestendinopathie (see also page 16 of protocol). Established diagnosis of maximum 3 months.

Exclusion criteria

Exclusion criteria: Tendonruptures History of ankle or Achillestendon operation Other explanations for pain Achillestendon (i.e. arthritis)

Design outcomes

Primary

Measure	Time frame
Earlier return to sport and daily-activities, based upon the VISA-A score.	—

Secondary

Measure	Time frame
Pain assessment, patient satisfaction, recurrence rate and ultrasound control	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)